Category: placement
-
Crescent Energy Announces Pricing of $250 Million Private Placement of Additional 7.375% Senior Notes Due 2033 By Investing.com
•
HOUSTON – (Business): Crescent Energy Corporation (NYSE: CRGY) (we or our) today announced that its indirect subsidiary, Crescent Energy Finance LLC (the Issuer) has priced its previously announced private offering pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”), to qualified…
-
FuelPositive Closes Final Tranche of Private Placement
•
This section is Partnership Content Provided The content in this section has been provided by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Globe Newswire Breadcrumbs Path Links Globe Newswire Article author: Published on August 31, 2024 •…
-
Arch Biopartners Closes Non-Brokered Private Placement
•
Article Content TORONTO, July 30, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Limited (“Arch” or the “Company”) (TSE: ARCH and OTCQB: ACHFF) today announced that it has closed the unconsented private placement disclosed in a press release dated July 29, 2024 (the “Offering”). Pursuant to the Offering, Arch issued 400,000 common…
-
Arch Biopartners Closes Non-Brokered Private Placement
•
Article Content TORONTO, July 30, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Limited (“Arch” or the “Company”) (TSE: ARCH and OTCQB: ACHFF) today announced that it has closed the unconsented private placement disclosed in a press release dated July 29, 2024 (the “Offering”). Pursuant to the Offering, Arch issued 400,000 common…
-
HydroGraph Announces Upsize of Private Placement to $3.2M
•
This section is Partnership content provided The content in this section is provided by GlobeNewswire for the purposes of press release distribution on behalf of its clients. Postmedia has not reviewed the content. by Globe Newswire Breadcrumb links Globe Newswire Article writer: Published on June 07, 2024 • 5 minute…
-
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
•
New York, May 16, 2024 /PRNewswire/ — Selous Therapeutics (NASDAQ:), Inc. (Nasdaq: SEEL) (“Seelos” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (“CNS”) disorders and rare diseases, announced today that it has entered into a securities purchase agreement agreement with certain investors. Institutional…